258 related articles for article (PubMed ID: 27439715)
21. HIV restriction by APOBEC3 in humanized mice.
Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
[TBL] [Abstract][Full Text] [Related]
22. Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction.
Song C; Sutton L; Johnson ME; D'Aquila RT; Donahue JP
J Biol Chem; 2012 May; 287(20):16965-74. PubMed ID: 22451677
[TBL] [Abstract][Full Text] [Related]
23. Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.
Meissner ME; Willkomm NA; Lucas J; Arndt WG; Aitken SF; Julik EJ; Baliga S; Mansky LM
J Mol Biol; 2022 Jan; 434(2):167355. PubMed ID: 34774569
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3DE Antagonizes Hepatitis B Virus Restriction Factors APOBEC3F and APOBEC3G.
Bouzidi MS; Caval V; Suspène R; Hallez C; Pineau P; Wain-Hobson S; Vartanian JP
J Mol Biol; 2016 Aug; 428(17):3514-28. PubMed ID: 27289067
[TBL] [Abstract][Full Text] [Related]
25. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.
Apolonia L; Schulz R; Curk T; Rocha P; Swanson CM; Schaller T; Ule J; Malim MH
PLoS Pathog; 2015 Jan; 11(1):e1004609. PubMed ID: 25590131
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.
Paprotka T; Venkatachari NJ; Chaipan C; Burdick R; Delviks-Frankenberry KA; Hu WS; Pathak VK
J Virol; 2010 Jun; 84(11):5719-29. PubMed ID: 20335265
[TBL] [Abstract][Full Text] [Related]
27. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.
Marin M; Golem S; Rose KM; Kozak SL; Kabat D
J Virol; 2008 Jan; 82(2):987-98. PubMed ID: 17977970
[TBL] [Abstract][Full Text] [Related]
28. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
29. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
Ooms M; Letko M; Binka M; Simon V
PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
[TBL] [Abstract][Full Text] [Related]
30. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
Liu B; Sarkis PT; Luo K; Yu Y; Yu XF
J Virol; 2005 Aug; 79(15):9579-87. PubMed ID: 16014920
[TBL] [Abstract][Full Text] [Related]
31. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.
Smith JL; Bu W; Burdick RC; Pathak VK
Trends Pharmacol Sci; 2009 Dec; 30(12):638-46. PubMed ID: 19837465
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3 degradation is the primary function of HIV-1 Vif for virus replication in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
bioRxiv; 2023 Mar; ():. PubMed ID: 37034786
[TBL] [Abstract][Full Text] [Related]
33. Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.
Amoêdo ND; Afonso AO; Cunha SM; Oliveira RH; Machado ES; Soares MA
PLoS One; 2011; 6(8):e24118. PubMed ID: 21897871
[TBL] [Abstract][Full Text] [Related]
34. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
[TBL] [Abstract][Full Text] [Related]
35. Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia.
An P; Penugonda S; Thorball CW; Bartha I; Goedert JJ; Donfield S; Buchbinder S; Binns-Roemer E; Kirk GD; Zhang W; Fellay J; Yu XF; Winkler CA
PLoS Genet; 2016 Mar; 12(3):e1005921. PubMed ID: 26942578
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 Vif adaptation to human APOBEC3H haplotypes.
Ooms M; Brayton B; Letko M; Maio SM; Pilcher CD; Hecht FM; Barbour JD; Simon V
Cell Host Microbe; 2013 Oct; 14(4):411-21. PubMed ID: 24139399
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Bélanger K; Langlois MA
J Gen Virol; 2015 Sep; 96(9):2878-2887. PubMed ID: 26048885
[TBL] [Abstract][Full Text] [Related]
38. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Kim EY; Lorenzo-Redondo R; Little SJ; Chung YS; Phalora PK; Maljkovic Berry I; Archer J; Penugonda S; Fischer W; Richman DD; Bhattacharya T; Malim MH; Wolinsky SM
PLoS Pathog; 2014 Jul; 10(7):e1004281. PubMed ID: 25080100
[TBL] [Abstract][Full Text] [Related]
39. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
[TBL] [Abstract][Full Text] [Related]
40. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.
Yamashita T; Kamada K; Hatcho K; Adachi A; Nomaguchi M
Microbes Infect; 2008; 10(10-11):1142-9. PubMed ID: 18603011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
